BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 239 filers reported holding BIO-TECHNE CORP in Q2 2015. The put-call ratio across all filers is 3.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $240,559 | -29.7% | 3,534 | -15.7% | 0.00% | -50.0% |
Q2 2023 | $342,030 | +54.3% | 4,190 | +40.2% | 0.00% | +100.0% |
Q1 2023 | $221,680 | +15.0% | 2,988 | +28.5% | 0.00% | 0.0% |
Q4 2022 | $192,696 | +96.6% | 2,325 | +575.9% | 0.00% | 0.0% |
Q3 2022 | $98,000 | -49.0% | 344 | -38.0% | 0.00% | 0.0% |
Q2 2022 | $192,000 | +16.4% | 555 | +45.3% | 0.00% | 0.0% |
Q1 2022 | $165,000 | +58.7% | 382 | +90.0% | 0.00% | – |
Q4 2021 | $104,000 | +42.5% | 201 | +33.1% | 0.00% | – |
Q3 2021 | $73,000 | +114.7% | 151 | +101.3% | 0.00% | – |
Q2 2021 | $34,000 | +47.8% | 75 | +23.0% | 0.00% | – |
Q1 2021 | $23,000 | -88.6% | 61 | -90.4% | 0.00% | -100.0% |
Q4 2020 | $201,000 | +53.4% | 634 | +20.1% | 0.00% | 0.0% |
Q3 2020 | $131,000 | -10.3% | 528 | -4.3% | 0.00% | 0.0% |
Q2 2020 | $146,000 | +8.1% | 552 | -22.6% | 0.00% | 0.0% |
Q1 2020 | $135,000 | -21.1% | 713 | -8.7% | 0.00% | 0.0% |
Q4 2019 | $171,000 | +37.9% | 781 | +23.2% | 0.00% | 0.0% |
Q3 2019 | $124,000 | -8.8% | 634 | -2.5% | 0.00% | 0.0% |
Q2 2019 | $136,000 | -14.5% | 650 | -18.8% | 0.00% | 0.0% |
Q1 2019 | $159,000 | +42.0% | 800 | +3.6% | 0.00% | 0.0% |
Q4 2018 | $112,000 | -29.1% | 772 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $158,000 | +33.9% | 772 | -3.4% | 0.00% | 0.0% |
Q2 2018 | $118,000 | -3.3% | 799 | -1.5% | 0.00% | 0.0% |
Q1 2018 | $122,000 | +48.8% | 811 | +28.7% | 0.00% | 0.0% |
Q4 2017 | $82,000 | +28.1% | 630 | +19.8% | 0.00% | – |
Q3 2017 | $64,000 | -1.5% | 526 | -5.6% | 0.00% | – |
Q2 2017 | $65,000 | +22.6% | 557 | +5.9% | 0.00% | – |
Q1 2017 | $53,000 | -1.9% | 526 | 0.0% | 0.00% | – |
Q4 2016 | $54,000 | -14.3% | 526 | -8.2% | 0.00% | -100.0% |
Q3 2016 | $63,000 | -4.5% | 573 | -2.7% | 0.00% | 0.0% |
Q2 2016 | $66,000 | +17.9% | 589 | -0.7% | 0.00% | – |
Q1 2016 | $56,000 | -6.7% | 593 | -10.4% | 0.00% | -100.0% |
Q4 2015 | $60,000 | -22.1% | 662 | -20.6% | 0.00% | 0.0% |
Q3 2015 | $77,000 | -6.1% | 834 | -0.2% | 0.00% | 0.0% |
Q2 2015 | $82,000 | -18.8% | 836 | -16.7% | 0.00% | 0.0% |
Q1 2015 | $101,000 | +13.5% | 1,003 | +4.6% | 0.00% | 0.0% |
Q4 2014 | $89,000 | – | 959 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |